ESTRO 2025 - Abstract Book

S1968

Clinical - Urology

ESTRO 2025

Conclusion: In line with published studies on UHF-RT, we report feasibility of UHF MR-guided RT for prostate cancer patients in clinical routine. Low acute and late toxicity rates have been demonstrated in our preliminary study. Very limited number of grade 3 toxicities were reported, whereas no invasive therapies were needed. Thus, these toxicities seem to be reversible and to normalize during follow-up corroborating the use of online adaptive MR-guided UHF-RT in prostate cancer in clinical routine.

Keywords: Prostate cancer, MR-Linac

1683

Poster Discussion Does curative radiotherapy impact fatigue onset in prostate cancer? An analysis of 1253 patients Paolo Bonome 1 , Milena Ferro 1 , Savino Cilla 2 , Mariangela Boccardi 1 , Marica Ferro 1 , Donato Pezzulla 1 , Vincenzo Picardi 1 , Carmela Romano 2 , Giuseppe Limosani 1 , Milly Buwenge 3 , Alessio Giuseppe Morganti 4,3 , Gabriella Macchia 1 , Francesco Deodato 1,5 1 Unit of Radiation Oncology, Responsible Research Hospital, Campobasso, Italy. 2 Medical Physics Unit, Responsible Research Hospital, Campobasso, Italy. 3 Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-Bologna University, Bologna, Italy. 4 Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 5 Istituto di Radiologia, Università Cattolica del Sacro Cuore, Roma, Italy Purpose/Objective: Fatigue is a symptom frequently related to cancer and its different treatments. The negative impact on the physical and psychological health of cancer patients is well reported. In this study, the impact of radiotherapy (RT) on the fatigue of prostate cancer (PC) patients was evaluated in a large population. Material/Methods: PC patients undergoing a radical treatment between December 2002 and September 2022 were retrospectively evaluated. Patient’s characteristics including age and comorbidities, Androgen -Deprivation Therapy (ADT), RT dose and fractionation, and related toxicities were registered. Fatigue level was measured through the Cancer Linear Analogue Scale (CLAS) for quality of life (CLAS1), energy level (CLAS2), and ability to perform daily activities (CLAS3). These parameters were assessed before RT (T0), and after one- (T1) and 12 months (T2). Two Scores (ScRT10 and